Medtronic (NYSE:MDT) today touted data from a pair of studies of its In.Pact Admiral drug-coated balloon, presented today at the annual Vascular Interventional Advances conference in Las Vegas.
Researchers revealed the formal cost-effectiveness analysis of the U.S. cohort of Medtronic’s In.Pact SFA trial, and in-stent restenosis cohort data from its In.Pact Global study.
Medtronic said the 2-year, prospective cost-effectiveness study of 181 patients showed that, although treatment with the drug-coated balloon was more expensive than with standard percutaneous transluminal angioplasty, costs were actually $100 lower over 2 years of follow-up, as the DCB-treated arm showed a significantly lower rate of target limb revascularization procedures. Index hospitalization costs with In.Pact Admiral were $8,293, compared with $7,164 for the PTA arm. That was offset by a reduction in follow-up costs for the DCB-treated group, at $2,984 over 2 years compared with $4,196 for the control group.
“While the index hospitalization costs were approximately $1,100 per patient higher in patients treated with DCB compared to standard PTA, over the 2-year follow up period, treatment costs were approximately $1,200 per patient less with DCB than standard PTA,” presenter Dr. David Cohen, of Saint Luke’s Mid America Heart Institute in Kansas City, said in prepared remarks. “This net economic advantage for In.Pact Admiral DCB was driven primarily by the significant reduction in target limb revascularization procedures with DCB over 2 years of follow up.”
Medtronic also released real-world data from a 1-year look at in-stent restenosis rates in 131 patients with complex ISR lesions, showing a 1-year primary patency rate of 88.7% and a clinically driven TLR rate of 7.3%.
“Results demonstrate effectiveness and safety of the In.Pact Admiral DCB in the treatment of patients with complex SFA lesions, including challenging ISR lesions,” said presenter Dr. Marianne Brodmann of the Medical University in Graz, Austria. “The primary patency is unmatched in this difficult to treat patient subgroup.”
“In.Pact Admiral DCB is a proven primary therapy for SFA disease. The latest clinical results demonstrating consistency, safety, efficacy and cost-effectiveness will continue to drive a paradigm shift in SFA interventions,” added Medtronic peripheral franchise general manager Brian Verrier. “Another key pillar of Medtronic’s mission is the ongoing pursuit of providing solutions which increase economic value within the healthcare system. We are proud to showcase our commitment to improving outcomes and increasing economic value through In.Pact Admiral DCB.”
